Pre-existing frontal lobe dysfunction signs as predictors of subsequent neurotoxicity in CAR T cell therapy: insights from a case series.
Lorenzo FontanelliChiara PizzanelliChiara MilanoRaffaella Cassano CassanoSara GalimbertiMaria Ida RossiniIgnazio SantoFrancesco TurcoEnrica BonanniGabriele SicilianoEnrico OrciuoloFilippo BaldacciPublished in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2023)
Based on our experience, we suggest that a pre-existing frontal lobe impairment, even if at a subclinical level, may eventually drive to ICANS, which in turn shows symptoms compatible with a frontal encephalopathy. It is remarkable that this focal neurotoxicity involved the same CNS regions that were responsible of subtle neurological signs at baseline. Future studies on larger numbers of patients are needed to confirm the possible role of baseline frontal lobe dysfunction as a predictor of ICANS, in order to enhance efforts to safely deliver CAR T cell therapy.
Keyphrases
- cell therapy
- functional connectivity
- working memory
- stem cells
- end stage renal disease
- mesenchymal stem cells
- ejection fraction
- chronic kidney disease
- prognostic factors
- oxidative stress
- peritoneal dialysis
- blood brain barrier
- living cells
- subarachnoid hemorrhage
- depressive symptoms
- patient reported outcomes
- sensitive detection
- fluorescent probe
- quality improvement
- case control